| Literature DB >> 16876403 |
Nobuhiko Kawanishi1, Tetsuya Sugimoto, Jun Shibata, Kaori Nakamura, Kouta Masutani, Mari Ikuta, Hiroshi Hirai.
Abstract
The design of a novel series of cyclin-dependent kinase (CDK) inhibitors containing a macrocyclic quinoxaline-2-one is reported. Structure-based drug design and optimization from the starting point of diarylurea 2, which we previously reported as a moderate CDK1,2,4,6 inhibitor [J. Biol.Chem.2001, 276, 27548], led to the discovery of potent CDK1,2,4,6 inhibitor that were suitable for iv administration for in vivo study.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16876403 DOI： 10.1016/j.bmcl.2006.07.026
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823